Background Lithium is a widely used and highly eff ective treatment for mood disorders, but causes poorly characterised adverse eff ects in kidney and endocrine systems. We aimed to analyse laboratory information system data to determine the incidence of renal, thyroid, and parathyroid dysfunction associated with lithium use.
Introduction
Mood disorders aff ect at least 350 million individuals worldwide and represent a substantial global burden of disease.
1 In high-income countries, unipolar depression is the leading cause of disability and morbidity.
1 Lithium is a widely used and eff ective treatment for mood disorders, protecting against both depression and mania and reducing risk of suicide. [2] [3] [4] [5] However, a narrow therapeutic index, which necessitates routine monitoring of serum concentrations, is one of the clinical disadvantages of lithium in practice. Lithium can also adversely aff ect the kidneys, thyroid, and parathyroid glands, so regular monitoring of renal and endocrine function is recommended. 6 The renal eff ects of lithium were fi rst reported more than 30 years ago, 7, 8 and investigators have begun characterising and quantifying these eff ects. 6, [9] [10] [11] Lithium causes three types of renal impairment: acute toxic eff ects, nephrogenic diabetes insipidus, and chronic renal dysfunction. Results of a meta analysis 6 of studies addressing lithium toxicity showed that little evidence existed for a clinically signifi cant reduction in renal function in most patients, and the risk of end-stage renal failure is low. However, substantial uncertainty remains because most of these studies were of short duration and unable to detect long-term eff ects. The risk of end-stage renal failure with lithium therapy has been estimated to be 0·5-1·0%; the risk factors for development of end-stage renal failure or for an accelerated decline in renal function remain unknown. 12, 13 Similarly, lithium therapy has been shown to disturb thyroid and parathyroid endocrine systems, but long-term follow-up studies are needed to characterise the incidence and risk factors.
We aimed to use laboratory information system data to determine the incidence of renal, thyroid, and parathyroid dysfunction caused by lithium use and to determine the strength of any associations noted.
Methods

Study design and participants
In this retrospective cohort study we extracted routinely collected data from the laboratory information system of the Clinical Biochemistry Department, Oxford University Hospitals NHS Trust. The laboratory performs routine tests for primary and secondary care for about 650 000 people in Oxfordshire, UK, and parts of neighbouring counties (Buckinghamshire, Northampton shire). The information system has been in operation continuously since 1985. Until 2003, the laboratory covering the northern part of Oxfordshire had a diff erent laboratory system, data from which were not included in this analysis.
The study cohort included all patients in the laboratory information system aged at least 18 years and with at least two measurements of serum creatinine, thyrotropin, calcium, glycated haemoglobin (HbA 1c ), or lithium taken between Oct 1, 1985, and March 31, 2014. The main exposure was lithium therapy (defi ned as more than two detectable serum lithium measurements), and all other patients of the same sex and age group but with no lithium measurements were non-exposed controls. We assumed non-Afro-Caribbean ethnicity because ethnicity is not recorded on the requests or our system.
No specifi c ethical approval was sought. BS is the keeper of the laboratory information system data, and all information used within the study was anonymised and not traceable to a single individual. The results of the analysis were not used to change clinical management in the patients studied.
Procedures
We estimated glomerular fi ltration rate from age, sex, and serum creatinine concentration with the MDRD 4-parameter equation (a UK standard for calculation of estimated glomerular fi ltration rate). For measurements of serum calcium concentration, if albumin concentration was measured on the same specimen, we adjusted the calcium concentration to an albumin concentration of 40 g/L with a factor of 0·02 mmol/L per g albumin/L diff erence from 40 g/L. We used the system database language (Intersystems Caché Objectscript) to defi ne for every patient the fi rst and last dates of measurement for each parameter, and the date (if applicable) when the (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) patient fi rst had a decline in renal function (estimated glomerular fi ltration rate <60 mL/min per 1·73 m²; stage three chronic kidney disease), hypothyroidism (thyrotropin activity >5·5 mU/L), hyperthyroidism (thyrotropin activity <0·2 mU/L), or a raised total or adjusted serum calcium concentration (>2·6 mmol/L).
Patients with an abnormal estimated glomerular fi ltration rate, thyrotropin activity, or calcium concentration at the fi rst measurement or who had no further measurements of the parameter being studied were excluded. For lithium measurements, we recorded the fi rst and last dates of measurement, the number of measurements ever requested, and the median and maximum lithium concentrations. For HbA 1c we inspected all measure ments, and defi ned any result of greater than 6·5% (48 mmol/mol) as consistent with a diagnosis of diabetes. Because laboratory investigation forms do not include the dose or regime of lithium treatment, no information as to dose or lithium formulation was available. The primary psychiatric diagnosis, polypharmacy, and medical comorbidities of the patient were unknown, although potential confounding by diabetes was investigated in the analysis.
Statistical analysis
We used R version 3.10 for statistical analysis, including the survival, ggplot2, plyr, and dplyr library modules. 14 We performed Cox proportional hazards analyses, with lithium use, age (years), sex, and diabetes as covariates. For each analysis, we checked for the signifi cance of the two-parameter interaction, that is, the likelihood that signifi cantly diff erent eff ects existed for diff erent age or sex groups. The output of each analysis is a summary giving the relative risk for the factors. We used a conventional signifi cance level of p<0·05, and did not adjust for multiple comparisons. We drew graphs of survival curves with an adaptation of the ggplot2 function "createSurvivalFrame". We tested the proportional hazards assumption for each analysis by plotting log(-log(survival)) against log(time).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. BS and RFM had full access to all the data. BS had fi nal responsibility for the decision to submit for publication and is guarantor.
Results
The laboratory information system contained data for 4678 patients who had serum lithium concentrations measured once (2795 [60%] of whom had more than one measurement) and 689 228 controls (table 1). Figure 1 shows the distributions of number of lithium measure ments (range 2-162), and fi gure 2 shows the distribution of time between fi rst and last lithium measurements (median 3·0, IQR 0·7-8·7 years, max 28 years). In patients with more than one lithium measurement, the median concentration was 0·6 (0·5-0·7) mmol/L.
After adjustment for age (cut-off 60 years), sex, and evidence of diabetes, presence of lithium was signifi cantly associated with stage three chronic kidney disease, hypothyroidism, and high total calcium concentration, but not with development of hyperthyroidism or high adjusted calcium concentration (table 2). Table 2 shows the hazard ratios for main factors (presence of lithium, age >60 years, sex, and diabetes) and the interaction terms (age >60 years with sex, age >60 years with lithium, and sex with lithium). The last four rows show the hazard ratios for the endpoint of interest for four diff erent age and sex groups (age cut-off 60 years and presence or absence of lithium) adjusted for evidence of diabetes. Kaplan-Meier estimates for association of lithium with development of stage 3 chronic kidney disease (fi gure 3) and hypothyroidism (fi gure 4) in subgroups show signifi cant diff erences depending on age, sex, and evidence of diabetes. For renal decline, young women without diabetes show the largest eff ect, with smaller eff ects in older men and women, and no increase in risk in younger men or in any of the subgroups with diabetes, perhaps because the numbers of patients with diabetes and taking lithium were small (table 2, fi gure 3). For development of hypothyroidism, the eff ect of lithium was signifi cant in all four age and sex subgroups, but greatest in younger women. However, in patients with evidence of diabetes, the only association was in older women (table 2, fi gure 4). For elevated total calcium concentration, there was a positive association in all subgroups except for younger men (table 2) .
In patients receiving lithium, median serum lithium concentrations higher than the overall median were associated with declines in renal function (estimated glomerular fi ltration rate <60 mL/min per 1·73 m²), high thyrotropin activity, high total serum calcium concentration, and high adjusted serum calcium concentration (table 3) . Length of time between fi rst and last lithium measurements greater than the median was associated with a reduced likelihood of each these outcomes (all HR <1; table 3), indicating that the eff ect was more likely to occur early. In patients receiving lithium, no association between the development of any of the endpoints and diabetes was found (table 3) . The distributions of median serum lithium concentrations were similar in men and women, and were not signifi cantly diff erent.
Discussion
Our results suggest that presence of lithium in serum is strongly associated with a decline in renal function and hypothyroidism, and less strongly with high total calcium concentrations. Young women had higher hazard ratios than other groups, suggesting that they are at greatest risk of renal disorder and hypothyroidism. High median serum lithium concentration seems to be a risk factor for all long-term complications of lithium use, although length of lithium treatment has a negative association, which suggests that the eff ects have rapid onset once patients start taking lithium.
In a large systematic review, 6 we reported that lithium use did not cause a clinically signifi cant decline in renal function. However, as we noted, a limitation of this review was that the included studies were very short-term, typically lasting 1-2 years. Our present results suggest that a patient receiving lithium is at high risk of developing at least stage three chronic kidney disease (table 2), and that the eff ect is observed quite soon after initiation of lithium treatment. Although stage three chronic kidney disease does not necessarily represent a clinically relevant decline in renal function, a subset of these patients might develop end-stage renal failure. We did not explore this possibility further in this study, but other studies 6, [11] [12] [13] 15 -including whole-country studies in Scandinavia and Australia-suggest that progression to end-stage renal failure is uncommon, with an absolute 
Data are HR (95% CI). Decline in renal function is defi ned by estimated glomerular fi ltration rate less than 60 mL/min per 1·73 m². Hypothyroidism is defi ned by thyrotropin activity greater than 5 mU/L. Hyperthyroidism is defi ned by thyrotropin activity less than 0·2 mU/L. HR=hazard ratio. risk of approximately 0·5-2%. Until now, the risk factors for serious renal damage have been unknown. From our analysis, increased serum lithium concentrations and young age in women seem to be associated with increased risk of decline in renal function. Further work with patients, for whom more detailed clinical and pharmaceutical information is available, will be needed to identify those at highest risk.
Our results are consistent with those of other studies with smaller sample sizes or shorter follow-up periods. Results of a small retrospective study 13 showed that use of lithium was associated with a modest decline in renal function and a very low risk of end-stage renal failure. Close and colleagues 11 report a similar magnitude of risk (HR 2·5) in their larger retrospective cohort study. A case−control study reported that patients taking lithium had 6·9% higher plasma creatinine concentrations and 7·3% lower estimated glomerular fi ltration rate compared with patients with other psychiatric conditions, matched for age, sex and, primary-care practice. 16 Study of a small prospective cohort, 17 followed for 4 years, showed no signifi cant diff erence in renal function between patients treated with lithium and controls. Rej and colleagues 17 reported that patients who do not develop chronic kidney disease early in lithium treatment are less likely to develop disease at later stages. However, this hypothesis assumes that non-toxic concentrations of lithium are maintained, because we show that a higher median lithium level does seem to be a risk factor for renal failure.
The pathophysiology of lithium-induced renal failure is unclear but seems to be of a chronic tubulointerstitial nephropathy with lesions suggestive of focal segmental glomerulosclerosis. 18 Renal cysts, which occur from the distal tubule and collecting ducts, might occur and can be visualised by MRI. 19, 20 Lithium-induced diabetes insipidus has been treated with the sodium channel blocker amiloride, with reasonable results. 21, 22 Preclinical results 23 from rodents have also suggested that lithiuminduced renal fi brosis might be reduced by treatment with amiloride.
All patients taking lithium therapy should have regular monitoring of renal function. The low risk of serious renal dysfunction should be balanced against the risks of the mood disorder and those of other mood stabilisers. From this study, young women and individuals who have a history of repeatedly high serum lithium concentrations seem to need closest monitoring. Data for lithium dosing and renal risk is scarce, so a sensible approach would be to minimise the dose of lithium used in general. The concentrations of lithium used in long-term treatment are usually lower than in treatment of acute mania, and these concentrations should be adhered to. Although the evidence for dose-response with lithium therapy is sparse, higher concentrations of lithium might be more protective in the maintenance phase, but at the cost of more adverse eff ects and lower adherence. Single daily dosing is probably better tolerated with respect to urinary frequency and is more likely to minimise the risk of nephrotoxic peak lithium levels. 24 Lithium was associated with hypothyroidism (raised thyrotropin concentration), consistent with results reported by McKnight and colleagues. 6 Individuals taking lithium, those aged more than 60 years, women, and people with diabetes all had a signifi cantly raised risk of hypothyroidism (table 2) . As with stage three chronic kidney disease, the risk of hypothyroidism seemed to be greatest at early stages of lithium treatment. Lithium was not associated with hyperthyroidism (suppressed thyrotropin activity). Previous studies reporting hyperthyroidism in response to lithium treatment have been heterogeneous in size and follow-up, but this study is the largest long-term report so far. In Data are HR (95% CI). Decline in renal function is defi ned as estimated glomerular fi ltration rate less than 60 ml/min per 1·73 m². Hypothyroidism is defi ned as thyrotropin activity greater than 5 mU/L. Hyperthyroidism is defi ned as thyrotropin activity less than 0·2 mU/L. HR=hazard ratio Table 3 : HR for renal failure, hypothyroidism, hyperthyroidism, and high serum calcium (total or adjusted) concentrations in patients taking lithium, by age, male sex, serum median lithium concentration, length of time between fi rst and last lithium measurements, and diabetes patients taking lithium we noted an increased risk of development of hyperthyroidism in patients with higher median lithium concentrations. Patients taking lithium, especially young women and those with high serum lithium concentrations, should have regular thyroid tests. Symptomatic hyperthyroidism should be treated, but it is unclear when hypothyroidism needs intervention, especially given the complex interaction between thyroid status and mood. In patients with treatment-resistant chronic low mood, treatment of biochemical (subclinical) hypothyroidism could be benefi cial.
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Little evidence is available to suggest what happens to thyroid function when lithium is withdrawn. Souza and colleagues 25 reported that thyroid function might normalise if lithium is stopped, but no similar studies have been published to date.
Although we noted an increased risk of raised total serum calcium concentration with lithium treatment, the risk was not signifi cant when adjusted serum calcium concentration was used. We noted signifi cant interactions between age, sex, and lithium, and therefore considerable heterogeneity between the subgroups on the basis of sex and age groups with a cut-point of 60 years (table 3) . Thus, women who are 60 years or more of age are at highest risk of high total and adjusted serum calcium concentrations. Whereas the risk for high total serum calcium concentration was increased in young women and elderly men, the risk was reduced in young men for adjusted serum calcium concentration.
We did not examine data to allow us to calculate the risk of a raised parathyroid hormone. Results of a previous meta-analysis 6 of 14 observational studies of calcium and parathyroid hormone concentrations in patients taking lithium (739 patients) compared with controls (699 controls) showed a 10% increase in both serum calcium and parathyroid hormone concentrations in patients taking lithium. Similarly, investigators of a large cross-sectional study 26 compared the serum calcium and parathyroid hormone concentrations of 204 patients who had been taking lithium for at least 6 years. Results showed a two-times increase in the rates of hypercalcaemia and hyperparathyroidism in cases compared with controls. In patients with bipolar disorder, serum parathyroid hormone and calcium concentrations have been reported 27 to be higher in patients taking lithium compared with patients who do not take lithium. These results suggest that there is a positive association between lithium and hyperparathyroidism. The physiological mechanism of this association is open to debate. Besides the physical complications related to hypercalcaemia, the association of lithium with low mood is also well documented. This association is highly relevant to patients on lithium, who frequently have mood disorders that are diffi cult to treat. As with thyroid disorders, these patients might benefi t from returning even mildly raised calcium to within normal parameters. All patients on lithium therapy should be advised to have calcium measured at baseline and at least annually thereafter.
The strengths of this study are the large number of individuals and the length of follow-up, with many people having specimens analysed throughout a period of more than 20 years. The main limitations are the heterogeneity of the study population, the limited information on the clinical features of patients, why the specimens were taken, what proportion of patients taking lithium have bipolar versus unipolar disorder, or any information of the doses of lithium taken. We have had to assume that during the period of regular measurements of serum lithium concentration, the patient was taking the lithium therapy regularly. Intermittent lithium therapy during the study period might also have aff ected the results, but this probably only concerns a few individuals and would indicate that the actual eff ects are larger than we suggest. Although we controlled for previous biochemical abnormalities and diabetes, other confounders, such as use of other psychotropic medications, could have aff ected the results. The fact that patients who took lithium had frequent measurements of serum creatinine concentration and thyrotropin activity would increase the likelihood that biochemical abnormalities were identifi ed.
Patients receiving long-term lithium treatment will usually have a chronic mood disorder causing con siderable morbidity and premature mortality. Lithium remains the
Panel: Research in context
Systematic review
The only comprehensive systematic review of the eff ect of lithium therapy on renal, thyroid, and parathyroid function was published by The Lancet in 2012. 6 The main fi ndings of this review were that lithium is associated with reduced urinary concentrating ability, hypothyroidism, and hyperparathyroidism. There was little evidence for a clinically signifi cant reduction in renal function and the absolute risk of renal failure was low. This systematic review was completed only shortly before this study began and therefore we judged no further update was needed.
Interpretation
With this retrospective cohort study, we set out to determine the strength of association between lithium therapy and renal, thyroid, and parathyroid dysfunction. This large study includes serum measurements given by 500 000 individuals during a 20 year period. The results show that lithium is associated with a decline in renal function (stage three chronic kidney disease), especially in young women and those with higher median lithium concentrations. Patients who are vulnerable to the nephrotoxic eff ect of lithium show a decline in renal function at an early stage of treatment. This fi nding is also true when test results were adjusted for the presence of hyperglycaemia. Lithium is also associated with hypothyroidism and, to a lesser extent, hypercalcaemia; the magnitude of these disorders are consistent with that of the above systematic review. 6 Our fi ndings suggest that close monitoring of adverse eff ects in all patients taking lithium is essential and that clinicians should work hard to use the lowest eff ective dose of lithium. This study is the fi rst to suggest some patient factors (sex, age) that might aff ect susceptibility to lithium nephrotoxicity; this area needs further exploration to allow as many patients as possible to benefi t from the gold standard mood stabiliser for bipolar disorder.
standard mood stabiliser for use in bipolar disorder and also reduces the risk of suicide. 4, 28 The evidence that lithium can adversely aff ect endocrine systems is clear, but clinically signifi cant conditions are either rare (renal function) or treatable (thyroid, parathyroid function). Other available drug treatments have signifi cant side eff ects and many are not recommended for use in young women. Lithium remains a key treatment, although its use needs monitoring and a safety-conscious approach is needed. 28 Young women and those with episodes of higher lithium serum levels are most at risk, and the risk often seems to be highest at early stages of treatment. Methods of early identifi cation of adverse eff ects and preventive strategies need improvement, and the risks and benefi ts of lithium withdrawal in patients who have developed adverse eff ects, but whom continue to derive clinical benefi t, should be studied further.
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